Characteristics of Patients with Chronic Obstructive Pulmonary Disease Treated with Long-Acting Bronchodilators in a Real-World Setting in Singapore: A Single-Center Observational Study

References

• World Health Organisation (WHO). The top 10 causes of death; 2021. Available from: https://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed June 2021.
   Google Scholar
• Ministry of Health Singapore. Principal causes of death; 2020. Available from: https://www.moh.gov.sg/resources-statistics/singapore-health-facts/principal-causes-of-death. Accessed June 2021.
   Google Scholar
• Epidemiology & Disease Control Division, Ministry of Health Singapore, Institute for Health Metrics and Evaluation. The Burden of Disease in Singapore, 1990–2017: An Overview of the Global Burden of Disease Study 2017 Results. Seattle, WA: IHME; 2019. Available from: https://www.healthdata.org/sites/default/files/files/policy_report/2019/GBD_2017_Singapore_Report.pdf. Accessed June 2021.
   Google Scholar
• Epidemiology & Disease Control Division, Ministry of Health Singapore. Singapore Burden of Disease Study 2010. Singapore: MoHS; 2014. Available from https://www.moh.gov.sg/docs/librariesprovider5/resources-statistics/reports/singapore-burden-of-disease-study-2010-report_v3.pdf. Accessed May 2021.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. GOLD; 2021. Available from https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf. Accessed May 2021.
   Google Scholar
• Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71(1):15–25. doi:10.1136/thoraxjnl-2014-206732
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832–840. doi:10.1183/09031936.04.00116004
   PubMed Web of Science ®Google Scholar
• Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62. 5/25mcg in COPD. Respir Med. 2013;107(10):1538–1546. doi:10.1016/j.rmed.2013.06.001
   PubMed Web of Science ®Google Scholar
• Maltais F, de la Hoz A, Casaburi R, O’Donnell D. Effects of Tiotropium/Olodaterol on Activity-Related Breathlessness, Exercise Endurance and Physical Activity in Patients with COPD: narrative Review with Meta-/Pooled Analyses. Adv Ther. 2021;38(2):835–853. doi:10.1007/s12325-020-01557-x
   PubMed Web of Science ®Google Scholar
• Calzetta L, Rogliani P, Matera MG, Cazzola M. A Systematic Review. with Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Chest. 2016;149(5):1181–1196. doi:10.1016/j.chest.2016.02.646
   PubMed Web of Science ®Google Scholar
• Agency for Care Effectiveness (ACE), Ministry of Health Singapore. Managing Stable Chronic Obstructive Pulmonary Disease. Singapore: MoHS; 2018. Available from: https://www.ace-hta.gov.sg/docs/default-source/acgs/managing-stable-copd—focusing-on-inhalers-(sep-2018).pdf. Accessed June 2021.
   Google Scholar
• Nici L, Mammen MJ, Charbek E, et al. Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69. doi:10.1164/rccm.202003-0625ST
   PubMed Web of Science ®Google Scholar
• Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889–904. doi:10.2147/COPD.S62750
   PubMed Web of Science ®Google Scholar
• Mannino DM, Yu TC, Zhou H, Higuchi K. Effects of GOLD-Adherent Prescribing on COPD Symptom Burden, Exacerbations, and Health Care Utilization in a Real-World Setting. Chronic Obstr Pulm Dis. 2015;2(3):223–235. doi:10.15326/jcopdf.2.3.2014.0151
   PubMedGoogle Scholar
• Kelly AM, Van Meer O, Keijzers G, et al. Get with the guidelines: management of chronic obstructive pulmonary disease in emergency departments in Europe and Australasia is sub-optimal. Intern Med J. 2020;50(2):200–208. doi:10.1111/imj.14323
   PubMed Web of Science ®Google Scholar
• Agency for Care Effectiveness (ACE), Ministry of Health Singapore. Long-Acting Muscarinic Antagonist (LAMA) Monotherapy and Combination Therapy with Long-Acting beta2 Agonists (LAMA/LABA) for the Treatment of Chronic Obstructive Pulmonary Disease. Singapore: ACE; 2018. Available from: https://www.ace-hta.gov.sg/docs/default-source/drug-guidances/lama-lama-laba-for-copd-(2-jul-2018).pdf. Accessed July 2018.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. GOLD; 2017. Available from: https://goldcopd.org/wp-content/uploads/2017/02/wms-GOLD-2017-FINAL.pdf. Accessed June 2021.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. GOLD; 2018. Available from: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf. Accessed June 2021.
   Google Scholar
• Ministry of Health Singapore. Chronic Obstructive Pulmonary Disease Clinical Practice Guideline; 2017. Available from: https://www.moh.gov.sg/docs/librariesprovider4/guidelines/copd.pdf. Accessed December 2021.
   Google Scholar
• Yii ACA, Loh CH, Tiew PY, et al. A clinical prediction model for hospitalized COPD exacerbations based on “treatable traits”. Int J Chron Obstruct Pulmon Dis. 2019;14:719–728. doi:10.2147/COPD.S194922
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Yanai M, Hanagama M, Yamanda S. Burden of chronic obstructive pulmonary disease in the elderly population. Respir Investig. 2014;52(5):296–301. doi:10.1016/j.resinv.2014.04.005
   PubMedGoogle Scholar
• Buikema AR, Brekke L, Anderson A, et al. The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models. Multidiscip Respir Med. 2018;13:38. doi:10.1186/s40248-018-0151-6
   PubMed Web of Science ®Google Scholar
• Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013;42(3):636–646. doi:10.1183/09031936.00195212
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: cohort Study in Real-World Clinical Practice. Chest. 2020;157(4):846–855. doi:10.1016/j.chest.2019.11.007
   PubMed Web of Science ®Google Scholar
• Agusti A, Fabbri LM, Singh D, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J. 2018;52(6):1801219. doi:10.1183/13993003.01219-2018
   PubMed Web of Science ®Google Scholar
• Dudvarski Ilic A, Zugic V, Zvezdin B, et al. Influence of inhaler technique on asthma and COPD control: a multicenter experience. Int J Chron Obstruct Pulmon Dis. 2016;11:2509–2517. doi:10.2147/COPD.S114576
   PubMed Web of Science ®Google Scholar
• Yu WC, Fu SN, Tai EL, et al. Spirometry is underused in the diagnosis and monitoring of patients with chronic obstructive pulmonary disease (COPD). Int J Chron Obstruct Pulmon Dis. 2013;8:389–395. doi:10.2147/COPD.S48659
   PubMed Web of Science ®Google Scholar
• Arne M, Lisspers K, Stallberg B, et al. How often is diagnosis of COPD confirmed with spirometry? Respir Med. 2010;104(4):550–556. doi:10.1016/j.rmed.2009.10.023
   PubMed Web of Science ®Google Scholar
• Perez X, Wisnivesky JP, Lurslurchachai L, Kleinman LC, Kronish IM. Barriers to adherence to COPD guidelines among primary care providers. Respir Med. 2012;106(3):374–381. doi:10.1016/j.rmed.2011.09.010
   PubMed Web of Science ®Google Scholar
• Ragaisiene G, Kibarskyte R, Gauronskaite R, et al. Diagnosing COPD in primary care: what has real life practice got to do with guidelines? Multidiscip Respir Med. 2019;14(1):28. doi:10.1186/s40248-019-0191-6
   PubMed Web of Science ®Google Scholar
• Vanjare N, Chhowala S, Madas S, Kodgule R, Gogtay J, Salvi S. Use of spirometry among chest physicians and primary care physicians in India. NPJ Prim Care Respir Med. 2016;26:16036. doi:10.1038/npjpcrm.2016.36
   PubMed Web of Science ®Google Scholar
• Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20(1):238. doi:10.1186/s12931-019-1193-9
   PubMed Web of Science ®Google Scholar
• Buhl R, de la Hoz A, Xue W, Singh D, Ferguson GT. Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naive to LAMA, LABA and ICS: pooled Analysis of Four Clinical Trials. Adv Ther. 2020;37(10):4175–4189. doi:10.1007/s12325-020-01411-0
   PubMed Web of Science ®Google Scholar